Price
No data yet.
Social Signal Score
Analyst Ratings
Company Profile
- CEO
- Kevin R. Lind
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 65
- Beta
- 0.00
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
APMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120-2.70%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·29d ago·Positive
Apnimed: What We Know Heading Into The Feb PDUFA Apnimed, Inc. (APMD) is a late-stage, de-risked regulatory play with a fully funded path to commercialisation, focused on AD109 for obstructive sleep apnea (OSA). AD109 (Oxnimbi) demonstrated robust Phase 3 efficacy, clear differentiation from CPAP, and manageable safety, with an NDA under FDA review and a February 2027 PDUFA date. APMD's financials show a transition from R&D to pre-commercial buildout, with a strong cash position and multiple yea…
View source ↗ - Newsglobenewswire.com·31d ago·Positive
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update.
View source ↗ - Newsproactiveinvestors.com·45d ago·Positive
Apnimed shares surge on bullish BofA initiation Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), Apnimed's sole asset and an oral therapy for obstructive sleep apnea (OSA).
View source ↗
Earnings
Typical surprise +905.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Sep 8$3.92 vs $-0.49beat
Estimates and results for APMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in APMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.